Spruce Biosciences (SPRB) Stock Forecast & Price Target

$51.06 +3.96 (+8.40%)

As of 11:43 AM Eastern

Compare

Spruce Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
1

Hold
2

Buy
7

Based on 10 Wall Street analysts who have issued ratings for Spruce Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 2 have given a hold rating, and 7 have given a buy rating for SPRB.

Consensus Price Target

$163.00
219.26% Upside

According to the 10 analysts' twelve-month price targets for Spruce Biosciences, the average price target is $163.00. The highest price target for SPRB is $283.00, while the lowest price target for SPRB is $123.00. The average price target represents a forecasted upside of 219.26% from the current price of $51.06.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SPRB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Spruce Biosciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SPRB Analyst Ratings Over Time

Type	Current Forecast 6/17/25 to 6/17/26	1 Month Ago 5/18/25 to 5/18/26	3 Months Ago 3/19/25 to 3/19/26	1 Year Ago 6/17/24 to 6/17/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	0 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$163.00	$186.60	$170.10	$131.25
Forecasted Upside	219.26% Upside	262.96% Upside	188.11% Upside	2,307.15% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

SPRB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SPRB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Spruce Biosciences Stock vs. The Competition

Type	Spruce Biosciences	Medical Companies	Broader Market
Consensus Rating Score	2.70	2.29	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	246.07% Upside	674.01% Upside	13.97% Upside
News Sentiment Rating	Positive News See Recent SPRB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/16/2026	Guggenheim 5 of 5 stars	Debjit Chattopadhyay 5 of 5 stars	Initiated Coverage	Buy	$123.00	+146.49%
6/9/2026	JonesTrading 3 of 5 stars	Catherine Novack Not Rated	Initiated Coverage	Buy	$135.00	+173.72%
6/5/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Sell (D-)
6/1/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Raghuram Selvaraju Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$200.00 ➝ $150.00	+192.57%
5/27/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
5/14/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Wolleben Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$170.00 ➝ $150.00	+162.51%
4/27/2026	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Albert Lowe Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$140.00	+157.49%
12/3/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$160.00	+79.37%
11/11/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
10/23/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
Read this warning immediately (Ad) Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Read Porter Stansberry's full breakdown and protect your wealth now
4/16/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$112.50 ➝ $37.50	+290.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:30 AM ET.

SPRB Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Spruce Biosciences is $163.00, with a high forecast of $283.00 and a low forecast of $123.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There is currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SPRB shares.

According to analysts, Spruce Biosciences's stock has a predicted upside of 219.26% based on their 12-month stock forecasts.

Spruce Biosciences has been rated by research analysts at Citizens Jmp, Craig Hallum, Guggenheim, HC Wainwright, JonesTrading, Oppenheimer, and Weiss Ratings in the past 90 days.

Analysts like Spruce Biosciences more than other "medical" companies. The consensus rating for Spruce Biosciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how SPRB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Spruce Biosciences Recommendations

This page (NASDAQ:SPRB) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Stock Forecast & Price Target

Spruce Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SPRB Analyst Ratings Over Time

SPRB Analyst Recommendations By Month

SPRB Price Targets by Month

Spruce Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

SPRB Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Spruce Biosciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Stock Forecast & Price Target

Spruce Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SPRB Analyst Ratings Over Time

SPRB Analyst Recommendations By Month

SPRB Price Targets by Month

Spruce Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

SPRB Forecast - Frequently Asked Questions

What is Spruce Biosciences' forecast for 2026?

Should I buy or sell Spruce Biosciences stock right now?

Does Spruce Biosciences's stock price have much upside?

What analysts cover Spruce Biosciences?

Do Wall Street analysts like Spruce Biosciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Spruce Biosciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools